Another successful quarter for Medicalgorithmics. Revenue up 18% y/y, with a 56% increase in the US market.
The medtech company listed on the Warsaw Stock Exchange continues to consistently implement its development strategy. In the second quarter of 2025, Medicalgorithmics acquired seven new large customers and entered new markets with its innovative services using advanced AI algorithms. Sales revenue amounted to nearly PLN 7.0 million, an increase of 18% y/y, and the number of tests performed grew by 37% y/y. Revenue from services in the US market, which is key for the company, increased by 56% y/y. Due to record interest in DRAI and DRP and integration with one of the largest IDTFs in the US, the Management Board of Medicalgorithmics expects further gradual revenue growth in the coming quarters of this year. In July and August alone, revenues grew by 33% and 30%, respectively, according to the company’s estimates. Since the beginning of 2025, the company has already signed 17 new contracts, including 4 in the US, compared to a total of 13 and 5 in the US in 2024, respectively.